<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03047811</url>
  </required_header>
  <id_info>
    <org_study_id>NY-TCR WXH 2016</org_study_id>
    <nct_id>NCT03047811</nct_id>
  </id_info>
  <brief_title>The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors</brief_title>
  <official_title>The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study of targeted NY-ESO-1 T cell receptor (TCR) genetic modified autologous T cells
      treatment of advanced solid tumors

        1. The main purpose - security and ORR;

        2. A secondary purpose - median progression-free surial;1 year, 2 years, total 5 years
           survival rate;The quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>From date of randomization until the date of date of death from any cause, whichever came first, assessed up to 36 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Advanced Malignant Solid Tumors</condition>
  <arm_group>
    <arm_group_label>TCR - T cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peripheral blood mononuclear cells collected: draw 100-150 ml of peripheral blood in patients and separate of the peripheral blood mononuclear cells, the total number of cells 1.5 * 10 ^ 7 / kg - 1 * 10 ^ 8 / kg Fludarabine 25 mg/m2 + NS 250 ml, ivgtt qdx5d, CTX 60 mg/kg + NS 250 ml, ivgtt qd x2d, should be in front of the TCR - T cells infusion of 4 days reinfusion the total number of T cells （1* 10 ^ 8 / kg - 10 * 10 ^ 8 / kg） in 3 days , infusion 10-15 minutes, should not be more than 20 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TCR - T cell therapy</intervention_name>
    <description>Low dose group: 1 x 10 ^8 /kg T cell total reinfusion. High dose groups: 10 x 10 ^ 8 / kgT cell total reinfusion.</description>
    <arm_group_label>TCR - T cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        3.1.1 volunteered for the clinical research and signed informed consent. 3.1.2 aged 18-70,
        expected lifetime &gt; 3 months. 3.1.3 gender not limited. 3.1.4 late lung cancer (stage
        IIIb/IV), (IV) with esophageal carcinoma, and melanoma (advanced), no other effective cure
        Treatment method can be selected patients. 3.1.5 biopsy IHC confirmed positive expression,
        NY - ESO - 1 or 50% of the tumor cells IHC staining in 2 + and/or 3 +.Organization based on
        time in the group in the year before, can be a tumor tissue, can also be a pleural effusion
        cells

        Exclusion Criteria:

        3.2.1 this study used in the process of cell preparation ingredients allergy, such as
        penicillin, streptomycin.

        3.2.2 used within a week of tyrosine kinase inhibitors (the treatment such as, for it), or
        other cancer drugs.

        3.2.3 is systemic anti-cancer therapy, including immune therapy, such as accept the immune
        cells within a month back to lose Therapy or biological treatment.6 weeks used cancer
        associated with tumor immune single resistance (including the PD, PD - L1 and - 1 CTLA 4
        single resistance). 3.2.4 have vital organs, such as cardiovascular, respiratory system
        disease, myocardial infarction, myocardial ischemia, the coronary artery bypass History or
        coronary ischemia symptoms, obstructive or restrictive lung disease. 3.2.5 the patient's
        immune tolerance is poor, may on the immune cells in treatment of the reaction of low or
        prone to toxic reactions.

        3.2.6 always have autoimmune and immunodeficiency disease. 3.2.7 radiation pneumonitis.
        3.2.8 depends on oxygen. 3.2.9 four weeks into the set of other therapeutic studies or
        clinical trials. 3.2.10 used experimental vaccine in two months 3.2.11 systemic
        corticosteroids used within two weeks, hydroxyurea or immune inhibitors (such as IL - 2,
        Interferons alpha, IFN - gamma, GSF, mTOR inhibitors, ring spore element, etc.).Recently or
        are using suction The sex hormone. 3.2.12 year have chronic or recurrent severe autoimmune
        diseases. 3.2.13 uncontrolled active infection. 3.2.14 2-4 acute or persistent during graft
        versus host disease (GVHD). 3.2.15 serious heart disease, after treatment of the disease is
        still unstable, into the group of the first six months after myocardial infarction, and
        congestion Heart failure, unstable angina, symptoms of pericardial effusion or unstable
        arrhythmia.

        3.2.18 always suffer from other cancers, but does not include: A. basal cell carcinoma and
        squamous cell carcinoma after active treatment, the wound healed completely.

        B. the cervical or breast carcinoma in situ cure for at least three years. C. primary
        malignant tumors were removed completely, completely relieve five years or more.

        3.2.19 accompanied by primary or secondary brain tumor patients. 3.2.20 the mentally
        disabled. 3.2.21 doubt or have alcohol and drug abuse history. 3.2.22 physicians determine
        cannot or may not be able to complete the test subjects.

        3.2.23 any not listed may interfere with the patient to participate in the active disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>xiang hua wu, doctor</last_name>
    <phone>13482888167</phone>
    <email>xhwu2011@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>xiang hua wu, dorctor</last_name>
    <phone>13482888167</phone>
    <email>xhwu2011@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wu X hua, doctor</last_name>
      <phone>13482888167</phone>
      <email>xhwu2011@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2017</study_first_submitted>
  <study_first_submitted_qc>February 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xianghua Wu</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

